KeyCorp Weighs in on Solventum’s FY2026 Earnings (NYSE:SOLV)

Solventum Corporation (NYSE:SOLV) – Equities researchers at KeyCorp dropped their FY2026 EPS estimates for shares of Solventum in a note issued to investors on Sunday, January 25th. KeyCorp analyst B. Fishbin now forecasts that the company will post earnings of $6.20 per share for the year, down from their previous estimate of $6.30. KeyCorp currently has a “Overweight” rating and a $97.00 price target on the stock. The consensus estimate for Solventum’s current full-year earnings is $6.58 per share.

SOLV has been the subject of a number of other research reports. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. UBS Group restated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Tuesday, December 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Tuesday. Finally, Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $90.83.

Solventum Stock Down 0.1%

Shares of SOLV opened at $76.52 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. Solventum has a 52 week low of $60.70 and a 52 week high of $88.20. The stock has a market capitalization of $13.27 billion, a price-to-earnings ratio of 8.82, a PEG ratio of 7.03 and a beta of 0.34. The stock has a fifty day moving average of $81.64 and a 200-day moving average of $75.78.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company’s quarterly revenue was up .7% on a year-over-year basis. During the same quarter last year, the business posted $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS.

Institutional Trading of Solventum

Institutional investors have recently added to or reduced their stakes in the stock. Hilltop National Bank raised its holdings in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum in the 3rd quarter worth approximately $25,000. JNBA Financial Advisors boosted its stake in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares during the last quarter. CYBER HORNET ETFs LLC acquired a new stake in shares of Solventum during the second quarter worth $28,000. Finally, Deseret Mutual Benefit Administrators raised its stake in Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares during the last quarter.

Solventum declared that its board has initiated a stock repurchase plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 7.5% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.